345 related articles for article (PubMed ID: 19364827)
41. Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells.
Taguchi K; Maruyama T; Otagiri M
Drug Metab Rev; 2011 Aug; 43(3):362-73. PubMed ID: 21428698
[TBL] [Abstract][Full Text] [Related]
42. Physical properties of hemoglobin vesicles as red cell substitutes.
Sakai H; Hamada K; Takeoka S; Nishide H; Tsuchida E
Biotechnol Prog; 1996; 12(1):119-25. PubMed ID: 8845102
[TBL] [Abstract][Full Text] [Related]
43. Kinetics of liposome-encapsulated hemoglobin after 25% hypovolemic exchange transfusion.
Awasthi VD; Garcia D; Klipper R; Phillips WT; Goins BA
Int J Pharm; 2004 Sep; 283(1-2):53-62. PubMed ID: 15363501
[TBL] [Abstract][Full Text] [Related]
44. Biocompatibility study of hemoglobin vesicles, cellular-type artificial oxygen carriers, with human umbilical cord hematopoietic stem/progenitor cells using an in vitro expansion system.
Yamaguchi M; Fujihara M; Wakamoto S; Sakai H; Takeoka S; Tsuchida E; Hamada H; Azuma H; Ikeda H
ASAIO J; 2009; 55(3):200-5. PubMed ID: 19282747
[TBL] [Abstract][Full Text] [Related]
45. [Progress in the red cell substitutes (artificial red cells)].
Tsuchida E
Rinsho Ketsueki; 1994 May; 35(5):439-45. PubMed ID: 8028190
[TBL] [Abstract][Full Text] [Related]
46. Complete deoxygenation from a hemoglobin solution by an electrochemical method and heat treatment for virus inactivation.
Huang Y; Takeoka S; Sakai H; Abe H; Hirayama J; Ikebuchi K; Ikeda H; Tsuchida E
Biotechnol Prog; 2002; 18(1):101-7. PubMed ID: 11822907
[TBL] [Abstract][Full Text] [Related]
47. Hemoglobin-vesicle, a cellular artificial oxygen carrier that fulfils the physiological roles of the red blood cell structure.
Sakai H; Sou K; Horinouchi H; Kobayashi K; Tsuchida E
Adv Exp Med Biol; 2010; 662():433-8. PubMed ID: 20204826
[TBL] [Abstract][Full Text] [Related]
48. Removal of cellular-type hemoglobin-based oxygen carrier (hemoglobin-vesicles) from blood using centrifugation and ultrafiltration.
Sakai H; Sou K; Horinouchi H; Tsuchida E; Kobayashi K
Artif Organs; 2012 Feb; 36(2):202-9. PubMed ID: 21834949
[TBL] [Abstract][Full Text] [Related]
49. PEGylation promotes hemoglobin tetramer dissociation.
Caccia D; Ronda L; Frassi R; Perrella M; Del Favero E; Bruno S; Pioselli B; Abbruzzetti S; Viappiani C; Mozzarelli A
Bioconjug Chem; 2009 Jul; 20(7):1356-66. PubMed ID: 19534518
[TBL] [Abstract][Full Text] [Related]
50. Pharmacokinetics and mechanisms of plasma removal of hemoglobin-based oxygen carriers.
Estep TN
Artif Cells Nanomed Biotechnol; 2015 Jun; 43(3):203-15. PubMed ID: 26024447
[TBL] [Abstract][Full Text] [Related]
51. Swine hemoglobin as a potential source of artificial oxygen carriers, hemoglobin-vesicles.
Sakai H; Ng K; Li B; Sugimura N
Artif Cells Nanomed Biotechnol; 2013 Feb; 41(1):37-41. PubMed ID: 22992176
[TBL] [Abstract][Full Text] [Related]
52. Pharmacokinetics and biodistribution of amikacin encapsulated in carrier erythrocytes.
Gutiérrez Millán C; Zarzuelo Castañeda A; González López F; Sayalero Marinero ML; Lanao JM
J Antimicrob Chemother; 2008 Feb; 61(2):375-81. PubMed ID: 18096557
[TBL] [Abstract][Full Text] [Related]
53. Effects of endogenous ascorbate on oxidation, oxygenation, and toxicokinetics of cell-free modified hemoglobin after exchange transfusion in rat and guinea pig.
Buehler PW; D'Agnillo F; Hoffman V; Alayash AI
J Pharmacol Exp Ther; 2007 Oct; 323(1):49-60. PubMed ID: 17622572
[TBL] [Abstract][Full Text] [Related]
54. Synthesis and characterization of a hemoglobin-ribavirin conjugate for targeted drug delivery.
Brookes S; Biessels P; Ng NF; Woods C; Bell DN; Adamson G
Bioconjug Chem; 2006; 17(2):530-7. PubMed ID: 16536487
[TBL] [Abstract][Full Text] [Related]
55. Liposome-Encapsulated Hemoglobin, TRM-645: Current Status of the Development and Important Issues for Clinical Application.
Kaneda S; Ishizuka T; Goto H; Kimura T; Inaba K; Kasukawa H
Artif Organs; 2009 Feb; 33(2):146-52. PubMed ID: 19178459
[TBL] [Abstract][Full Text] [Related]
56. S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts.
Asanuma H; Nakai K; Sanada S; Minamino T; Takashima S; Ogita H; Fujita M; Hirata A; Wakeno M; Takahama H; Kim J; Asakura M; Sakuma I; Kitabatake A; Hori M; Komamura K; Kitakaze M
J Mol Cell Cardiol; 2007 May; 42(5):924-30. PubMed ID: 17234208
[TBL] [Abstract][Full Text] [Related]
57. Biological evaluation of N-octyl-O-sulfate chitosan as a new nano-carrier of intravenous drugs.
Zhang C; Qu G; Sun Y; Yang T; Yao Z; Shen W; Shen Z; Ding Q; Zhou H; Ping Q
Eur J Pharm Sci; 2008 Apr; 33(4-5):415-23. PubMed ID: 18337069
[TBL] [Abstract][Full Text] [Related]
58. In vivo evaluation of pyridoxalated-polymerized hemoglobin solution.
Friedman HI; De Venuto F; Schwartz BD; Nemeth TJ
Surg Gynecol Obstet; 1984 Nov; 159(5):429-35. PubMed ID: 6495140
[TBL] [Abstract][Full Text] [Related]
59. Hemoglobin vesicles containing methemoglobin and L-tyrosine to suppress methemoglobin formation in vitro and in vivo.
Atoji T; Aihara M; Sakai H; Tsuchida E; Takeoka S
Bioconjug Chem; 2006; 17(5):1241-5. PubMed ID: 16984134
[TBL] [Abstract][Full Text] [Related]
60. [The distribution of azidothymidine palmitate galactosylated liposomes in mice].
Wu HB; Deng YH; Wang SN; Zhou XY; Wang N; Shi L
Yao Xue Xue Bao; 2007 May; 42(5):538-44. PubMed ID: 17703780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
